B+
Bull case
20%
Probability
Target price
$6.20
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
OKUR
OnKure TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The reported cash position may fund both lead programs through important regulatory transitions, and successful IND submissions for OKI-355 and OKI-345 could support substantial re-rating from the $3.10 anchor. Management believes mutant-selective PI3Kα inhibition may improve therapeutic index, but that proposition remains unvalidated clinically [#SEC-8K-2026-08-04].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.1.
What can break
Both lead candidates remain preclinical, with no patient efficacy or clinical safety data in the packet.
Momentum
43
Value
59
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $6.20 · Bear $1.50Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $15.50
Why
Momentum43 · Δ7d +8.3
Value59 · Δ7d 0.0
Sentiment87 · Δ7d -0.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Both lead candidates remain preclinical, with no patient efficacy or clinical safety data in the packet.
- • FDA questions, IND delays or adverse preclinical findings could materially impair either program before clinical validation.
- • Both lead assets remain in IND-enabling development, leaving valuation dependent on preclinical execution, FDA clearance and eventual human safety and efficacy.
Catalyst clock
2026-11-30
Cash runway limits near-term financing pressure
Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendSoftening
Δ7d
+8.3
Δ21d
-11.5
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.4
Sentiment
87
62% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+4.1
Why this grade
Composite grade A. Momentum 42.9 / Value 58.5 / Sentiment 86.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$166.44M
Beta
0.47
Shares Out
40.5M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.39
Rev YoY
-
EPS YoY
-73.0%
Gross Margin
-
Op Margin
-
Net Debt
-$58.5M
Current Ratio
26.75
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data